Sector News

Activist fund Sarissa wants to oust Ariad CEO

February 13, 2015
Life sciences
Activist hedge fund Sarissa Capital, which won a seat on Ariad Pharmaceuticals’ board last year, is seeking to replace the company’s chief executive and may mount a proxy fight in the next few weeks, according to a person familiar with the hedge fund’s plans.
 
Sarissa is the largest shareholder of Ariad, with 6.9 percent of the stock, or about 12.9 million shares, according to FactSet. The hedge fund is run by Alex Denner, formerly Carl Icahn’s head of biotech investing, and Richard Mulligan, a Harvard geneticist who worked with Denner and Icahn on several investments.
 
Sarissa has been agitating at Ariad since October 2013, when the drugmaker’s stock plummeted over safety concerns with its cancer drug, Iclusig. Denner won a seat on the board in February 2014 and the right to add a second director to be agreed on with the company. Ariad and Sarissa haven’t named that second board member.
 
“It’s pretty interesting there is some quote-unquote activism here, but it’s been pretty quiet,” RBC Capital Markets analyst Michael Yee said in a telephone interview. “Typically activists come in and start to make noise, write an open letter, demand changes, send tweets, whatever it is; none of that has actually happened.”
 
That may be about to change. Sarissa is said to be seeking to replace Chief Executive Officer Harvey Berger, the company’s founder; Berger is up for re-election this year, along with two other members of the eight-member board. The notification date for new director proposals is Feb. 25, according to Ariad’s 2014 proxy filing. The hedge fund may not seek a proxy fight in the coming weeks if an agreement is reached with the company.
 
Maria Cantor, a spokeswoman for Ariad, declined to comment.
 
The company is working to regain investor confidence in the prospects of Iclusig after it was pulled from the U.S. market at the end of 2013 over safety concerns. It returned two months later, with more restrictions on its use. Ariad shares have fallen about 17 percent in the last 12 months, compared with an increase of 25 percent for the Nasdaq Biotechnology Index.
 
“Commercially, we’ve had a really good year; we’ve really made progress in the U.S. as well as Europe,” Berger said in an interview with CNBC at the J.P. Morgan Health Care Conference in January.
 
In response to a question about Denner and the potential for a proxy fight, he said: “I have no idea at this point, but certainly he’s been a productive and cooperative member of the board. He’s been involved in things and is part of a very involved board of directors.”
 
By Meg Tirrell
 
Source: CNBC
 

comments closed

Related News

October 23, 2021

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Life sciences

As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.

October 23, 2021

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody

Life sciences

The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.

October 23, 2021

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.

Send this to a friend